On Monday, Cognition Therapeutics Inc (NASDAQ: CGTX) opened lower -2.56% from the last session, before settling in for the closing price of $0.63. Price fluctuations for CGTX have ranged from $0.34 to $2.95 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -0.78% at the time writing. With a float of $35.21 million, this company’s outstanding shares have now reached $40.81 million.
The firm has a total of 28 workers. Let’s measure their productivity. In terms of profitability, gross margin is 48.66%, operating margin of -15707.53%, and the pretax margin is -9212.37%.
Cognition Therapeutics Inc (CGTX) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Cognition Therapeutics Inc is 15.24%, while institutional ownership is 10.36%. The most recent insider transaction that took place on Mar 14 ’24, was worth 9,975. In this transaction CEO & President of this company bought 5,700 shares at a rate of $1.75, taking the stock ownership to the 291,345 shares.
Cognition Therapeutics Inc (CGTX) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -0.78% per share during the next fiscal year.
Cognition Therapeutics Inc (NASDAQ: CGTX) Trading Performance Indicators
Check out the current performance indicators for Cognition Therapeutics Inc (CGTX). In the past quarter, the stock posted a quick ratio of 2.11.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.96, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.76 in one year’s time.
Technical Analysis of Cognition Therapeutics Inc (CGTX)
Analysing the last 5-days average volume posted by the [Cognition Therapeutics Inc, CGTX], we can find that recorded value of 66.86 million was better than the volume posted last year of 2.09 million. As of the previous 9 days, the stock’s Stochastic %D was 25.02%. Additionally, its Average True Range was 0.10.
During the past 100 days, Cognition Therapeutics Inc’s (CGTX) raw stochastic average was set at 28.84%, which indicates a significant increase from 26.11% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 130.59% in the past 14 days, which was higher than the 107.23% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.4831, while its 200-day Moving Average is $1.2269. Now, the first resistance to watch is $0.6389. This is followed by the second major resistance level at $0.6638. The third major resistance level sits at $0.6976. If the price goes on to break the first support level at $0.5802, it is likely to go to the next support level at $0.5464. Should the price break the second support level, the third support level stands at $0.5215.
Cognition Therapeutics Inc (NASDAQ: CGTX) Key Stats
There are currently 41,548K shares outstanding in the company with a market cap of 25.51 million. Presently, the company’s annual sales total 0 K according to its annual income of -25,790 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -9,940 K.
